-
Sector Analysis
Spinal Muscular Atrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Spinal Muscular Atrophy (SMA) market through 2033. The diagnosed prevalent cases of SMA across the seven major markets are expected to increase from 18,621 cases in 2023 to 19,202 cases by 2033. The SMA market across the 7MM was valued at $2.7 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at...
-
Product Insights
Spinal Muscular Atrophy (SMA) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Spinal Muscular Atrophy (SMA) Clinical Trial Report Overview A total of 230 spinal muscular atrophy (SMA) clinical trials have been conducted as of July 2024. The spinal muscular atrophy (SMA) clinical trial report provides a comprehensive understanding of the spinal muscular atrophy (SMA) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated...
-
Product Insights
Spinal Muscular Atrophy (SMA) - Drugs In Development, 2024
Empower your strategies with our Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024 report and make more profitable business decisions. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms...
-
Sector Analysis
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Report Overview Spinal muscular atrophy (SMA) is a group of inherited neuromuscular disorders. These disorders are clinically and genetically heterogeneous. The primary feature is the loss of lower motor neurons in the spinal cord. This results in progressive muscle weakness, muscle wasting, and low muscle tone. However, neurons controlling most voluntary muscles like those involved in feeding, swallowing, and breathing can also be affected. Key Mechanism of Action (Marketed) ·      Protein or...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.